You are here

P&T® Journal contents for January 2004


Biotechnology Update
Dr. Goldenberg reviews the risks associated with some biological agents, which had been heralded as a breakthrough in the treatment of certain medical conditions.
Marvin M. Goldenberg, PhD, RPh, MS
The authors describe a pilot study during which many interventions resulted in a cost savings of more than $124,000 and enhanced patient care.
Timothy R. Pasquale, PharmD, Kenneth M. Komorny, PharmD, BCPS, Dorcas Letting-Mangira, PharmD, and Stephanie Peshek, PharmD
The authors explain how developing new guidelines at one hospital has improved the quality of care and has reduced the length of stay for patients with community-acquired pneumonia.
Paul D. Santos, PharmD, A. Frederick Hartman, MD, MPH, Susan S. Irving, RN, MPH, Sanjay Merchant, PhD, MBA, Brian Meissner, PharmD, Eileen M. Farrelly, MPH, and Kristine M. Floyd, PharmD
Dr. Greengold discusses a moral and intellectual dilemma faced by P&T committees everywhere: deciding when there is enough evidence to add a drug to the formulary.
Nancy L. Greengold, MD, MBA
Marvin M. Goldenberg, PhD, RPh, MS
Editorial Board Spotlight
Sonja Sherritze


David Nash, MD, MBA, provides some options for countering the problem of counterfeit drugs.
David Nash, MD, MBA
Editor’s Memo
Sonja Sherritze presents her modest New Year’s resolutions for P&T.
Sonja Sherritze
Prescription Washington
Stephen Barlas discusses the ramifications of the new Medicare prescription drug benefit.
Stephen Barlas
Medication Errors
Matthew Grissinger, RPh, FASCP, describes a near-fatal accident in a child after a syringe of medication was mistaken for a saline solution because of look-alike labeling.
Matthew Grissinger, RPh, FASCP
P&T presents the latest studies and information about FDA approvals, drug indications, industry updates, and new medical devices.
Drug Forecast
The authors describe the role of hydroxyurea (Droxia®) in the treatment of sickle cell anemia.